Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

terminated125%
unknown125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

NCT04735068
terminatedphase_1

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

NCT04873895
unknownphase_2

Hydroxychloroquine and Indapamide in SPMS

NCT05013463
completed

COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience

NCT04554979

Clinical Trials (4)

Showing 4 of 4 trials
NCT04735068Phase 2

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Completed
NCT04873895Phase 1

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

Terminated
NCT05013463Phase 2

Hydroxychloroquine and Indapamide in SPMS

Unknown
NCT04554979

COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4